舍曲林与安慰剂在接受血液透析的重性抑郁障碍患者中的比较:一项随机对照可行性试验
这项多中心、随机、双盲、安慰剂对照可行性试验在五个英国肾脏中心筛查709例血液透析患者,纳入30例重性抑郁障碍患者随机接受舍曲林或安慰剂治疗6个月。舍曲林组因不良事件和严重不良事件脱落的例数更多,且均发生在头3个月;两组抑郁评分均改善,舍曲林与安慰剂组间无差异;试验样本量小且脱落率高,获益考量尚不确定。
要点
- 筛查709例血液透析患者,231例(32.6%)贝克抑郁量表II评分≥16,最终仅30例随机分组。
- 完成试验者舍曲林组8/15例、安慰剂组13/15例(P=0.05)。
- 舍曲林组因不良事件和严重不良事件脱落更多,均发生于头3个月;两组抑郁评分均改善且组间无差异。
核心结论
- 尽管样本量小,这是迄今规模最大的血液透析患者抗抑郁药随机试验;结果凸显招募问题。
- 未观察到获益,但试验规模和大量脱落使获益考量尚无定论。
- 一项决定性试验可采用更短随访,并纳入已在服用抗抑郁药的抑郁患者。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照可行性试验,在英国五个肾脏中心进行,为期6个月。
- 709例血液透析患者于2013年4月至2014年10月间筛查入组;贝克抑郁量表II评分≥16且未接受抑郁治疗者受邀进行诊断性访谈。
- 确诊重性抑郁障碍的合格患者随机接受舍曲林或安慰剂;30例随机分组,21例完成试验(舍曲林组8/15例,安慰剂组13/15例,P=0.05)。
- 结局包括招募率和脱落率、蒙哥马利-阿斯伯格抑郁评定量表与贝克抑郁量表II评分变化,以及指导大型试验设计的定性信息。
主要发现
- 709例筛查患者中231例(32.6%)贝克抑郁量表II评分≥16,其中68例(29%)已在接受抑郁治疗。
- 63例接受诊断性访谈,37例诊断重性抑郁障碍,30例随机分组。
- 完成试验者舍曲林组8/15例 vs 安慰剂组13/15例(P=0.05)。
- 舍曲林组因不良事件和严重不良事件脱落更多,均发生在头3个月。
- 6个月内两组抑郁评分均改善:贝克抑郁量表II评分从29.1±8.4降至17.3±12.4(P<0.001),蒙哥马利-阿斯伯格抑郁评定量表评分从24.5±4.1降至10.3±5.8(P<0.001);舍曲林与安慰剂组间无差异。
局限性
- 样本量小。
- 脱落率高(完成试验者舍曲林组8/15例 vs 安慰剂组13/15例,P=0.05)。
- 试验规模与大量脱落使获益考量尚无定论。
- 结果凸显招募问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Depression is common in patients on hemodialysis, but data on the benefits and risks of antidepressants in this setting are limited. We conducted a multicenter, randomized, double-blind, placebo-controlled trial of sertraline over 6 months in patients on hemodialysis with depression to determine study feasibility, safety, and effectiveness. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Patients on hemodialysis at five United Kingdom renal centers completed the Beck Depression Inventory II. Those scoring ≥16 and not already on treatment for depression were invited to undergo diagnostic interview to confirm major depressive disorder. Eligible patients with major depressive disorder were randomized to receive the study medication-either sertraline or placebo. Outcomes included recruitment and dropout rates, change in the Montgomery-Asberg Depression Rating Scale and Beck Depression Inventory II, and qualitative information to guide design of a large-scale trial. RESULTS: In total, 709 patients were screened and enrolled between April of 2013 and October of 2014; 231 (32.6%) had Beck Depression Inventory II scores ≥16, and 68 (29%) of these were already receiving treatment for depression. Sixty-three underwent diagnostic interview, 37 were diagnosed with major depressive disorder, and 30 were randomized; 21 completed the trial: eight of 15 on sertraline and 13 of 15 on placebo (P=0.05). Dropouts due to adverse and serious adverse events were greater in the sertraline group. All occurred in the first 3 months. Over 6 months, depression scores improved in both groups. Beck Depression Inventory II score fell from 29.1±8.4 to 17.3±12.4 (P<0.001), and Montgomery-Asberg Depression Rating Scale score fell from 24.5±4.1 to 10.3±5.8 (P<0.001). There were no differences between sertraline and placebo groups. CONCLUSIONS: Although small, this is the largest randomized trial to date of antidepressant medication in patients on hemodialysis. Our results highlight recruitment issues. No benefit was observed, but trial size and the substantial dropout render consideration of benefit inconclusive. A definitive trial could use shorter follow-up and include depressed patients already taking antidepressants.
引用
- Friedli K, Guirguis A, Almond M, et al. Sertraline Versus Placebo in Patients with Major Depressive Disorder Undergoing Hemodialysis: A Randomized, Controlled Feasibility Trial. Clin J Am Soc Nephrol. 2017. PMID: 28126706. doi:10.2215/CJN.02120216
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。